 CAMBRIDGE, Mass., March 15, 2021 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. NASDAQ: RUBY Rubius, a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell TherapeuticsTM, today announces that it has commenced an underwritten public offering of 150 million of shares of its common stock. Rubius also intends to grant the underwriters a 30-day option to purchase up to an additional 15 of the shares of its common stock sold in the public offering. All the shares in the offering are to be sold by Rubius. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. 